Cue Biopharma Inc expected to post a loss of 31 cents a share - Earnings Preview

Cue Biopharma

17/03/2023 20:32

* Cue Biopharma Inc  CUE.OQ   CUE.O  is expected to show a
fall in
quarterly revenue when it reports  results on March 21. 
    * The Boston Massachusetts-based  company is expected to
report  a
98.7% decrease in revenue to $103.75 thousand from $8.25 million
a year ago, according to the mean estimate from 4 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Cue Biopharma Inc
is for
a loss of 31 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Cue
Biopharma Inc
is $9.5​, above​ its last closing price of $3.09. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.38       -0.38      -0.31     Beat    18.4
 Jun. 30 2022  -0.43       -0.42      -0.37     Beat    12.6
 Mar. 31 2022  -0.43       -0.43      -0.44     Missed  -2.9​
 Dec. 31 2021  -0.45       -0.38      -0.25     Beat    35.1
 ​​Sep.        -0.38       -0.39      -0.41     Missed  -5.1
 30 2021                                                
 Jun. 30 2021  -0.41       -0.42      -0.33     Beat    20.7​
 Mar. 31 2021  -0.38       -0.38      -0.41     Missed  -8.5
 Dec. 31 2020  -0.35       -0.35      -0.36     Missed  -2.9
 This summary was machine generated March 17 at 20:32 GMT.  All
figures in US dollars  unless otherwise stated